MED19 antibody (AA 51-150) (FITC)
Quick Overview for MED19 antibody (AA 51-150) (FITC) (ABIN6987018)
Target
See all MED19 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 51-150
-
Cross-Reactivity
- Rat
-
Predicted Reactivity
- Human,Mouse,Cow,Horse,Chicken
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human MED19/LCMR1
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- MED19 (Mediator Complex Subunit 19 (MED19))
-
Alternative Name
- MED19
-
Background
-
Synonyms: LCMR1, Lung cancer metastasis related protein 1, Lung cancer metastasis-related protein 1, med19, MED19_HUMAN, Mediator complex subunit 19, Mediator of RNA polymerase II transcription subunit 19, Mediator of RNA polymerase II transcription, subunit 19 homolog.
Background: MED19 is a component of the Mediator complex, which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (Sato et al., 2003 [PubMed 12584197]).[supplied by OMIM, Oct 2008]
-
Gene ID
- 219541
-
UniProt
- A0JLT2
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha
Target
-